Management to host webcast on April 1, 2022, at 11.30 a.m. CET / 5.30 a.m. ET

Oslo, Norway, March 28, 2022 - Nykode Therapeutics AS (Euronext Growth (Oslo):
NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and
development of vaccines and novel immunotherapies, today announced it will
report its full year 2021 financial results on March 31, 2022 after market
close. Investors and analysts are invited to join a webcast presentation of the
2021 financial results conducted by CEO Michael Engsig and other members of
management on April 1, 2022, at 11.30 a.m. CET / 5.30 a.m. ET.

An updated corporate presentation will be available in the Investors section of
the Company's website at 7:00 a.m. CET on April 1 at www.nykode.com/investors.
The live and archived webcast of the presentation can be accessed in the
Investors section of the Company's website
www.nykode.com/investors/financial-reports-and-presentations.  


Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of vaccines and novel immunotherapies for the
treatment of cancer and infectious diseases. Nykode's modular vaccine technology
specifically targets antigens to Antigen Presenting Cells, which are essential
for inducing rapid, strong and long-lasting antigen specific immune responses
and eliciting efficacious clinical responses. 

Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of human papilloma virus 16 induced malignancies which is in Phase 2
for the treatment of cervical cancer